MediGene
From Wikipedia, the free encyclopedia
 |
|
| Type | Aktiengesellschaft |
|---|---|
| Traded as | FWB: MDG |
| Industry | Biotechnology |
| Predecessor(s) | Munich Gene Center |
| Founded | 1994 |
| Headquarters | Martinsried, Germany |
| Key people | Frank Mathias (CEO), Ernst-Ludwig Winnacker (Chairman of the supervisory board) |
| Products | Pharmaceuticals for treatment of cancer and autoimmune diseases |
| Revenue | €37.9 million (2009)[1] |
| Operating income |  (€19.6 million) (2009)[1] |
| Profit | (€22.0 million) (2009)[1] |
| Employees | 110 (end 2009)[1] |
| Website | www.medigene.de |
MediGene AG is a German biotechnology company. It is involved in the development of anti pancreatic cancer drugs.[2] The company has two marketed products: Eligard (leuprorelin) for prostate cancer and Veregen (sinecatechins) for genital warts. It has three other products in clinical development for the treatment of hormone-resistant breast cancer, pancreatic cancer and rheumatoid arthritis.
[edit] References
- ^ a b c d "Annual Report 2009". MediGene. http://www.medigene.de/mediadb/9739/9740/AnnualReport2009.pdf. Retrieved 22 August 2010.
- ^ "MediGene drug extends pancreatic cancer survival". Reuters. 2008-09-18. http://www.reuters.com/article/marketsNews/idUSLG43985820080916?sp=true.
[edit] External links
 |
This German corporation or company article is a stub. You can help Wikipedia by expanding it. |
